N-(2,6-dimethylphenyl)-2-<4-(2-pyridynyl)-1-piperazinyl>acetamide | 86523-70-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-(2,6-dimethylphenyl)-2-<4-(2-pyridynyl)-1-piperazinyl>acetamide
• 英文别名: N-(2,6-dimethylphenyl)-2-[4-(2-pyridinyl)-1-piperazinyl]acetamide；N-(2,6-dimethylphenyl)-2-[4-(2-pyridynyl)-1-piperazinyl]acetamide；N-(2,6-dimethylphenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)acetamide
• CAS: 86523-70-8
• 化学式: C₁₉H₂₄N₄O
• mdl: MFCD05147216
• 分子量: 324.426
• InChiKey: JLGAQXSAVCLCBI-UHFFFAOYSA-N

物化性质

• 熔点：
  144-145 °C(Solv: ethanol (64-17-5))
• 沸点：
  513.4±50.0 °C(Predicted)
• 密度：
  1.170±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  48.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(2-吡啶基)哌嗪 、 2,6-二甲基氯代乙酰苯胺 在 sodium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 、 水 为溶剂， 反应 18.0h， 以99.9%的产率得到N-(2,6-dimethylphenyl)-2-<4-(2-pyridynyl)-1-piperazinyl>acetamide
  参考文献：
  名称：

  Acetamides and benzamides that are useful in treating sexual dysfunction

  摘要：

  本发明涉及使用式（I）的化合物治疗性功能障碍，以及含有式（I）化合物的组合物用于治疗性功能障碍。

  公开号：

  US20030229094A1

文献信息

• Alkanoylanilides
  申请人：RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY

  公开号：EP0074768A2

  公开（公告）日：1983-03-23

  ω-[4-(2-pyridyl)-piperazino]-alkanoylanilide derivatives of the general formula I are provided. In the formula, n = 1, 2 or 3, each of R, R,, RZ, R3 and R4 is independently H, halogen, alkyl, alkoxy, OH, NH2, CF3, CN, alkylthio, 1-hydroxyalkyl, alkanoyl, NH2CO, NH2SO2, alkoxycarbonyl, alkylsulphonyl, benzyloxy, alkanoylamino, NH2CONH, 3-phenylureido. 3-alkylureido or alkoxyoxalylamino, R5 = H or alkyl, R6 = H or alkoxy. These compounds and their pharmaceutically acceptable salts have antianaphylactic, antibronchospastic, antihistaminic, sedative, analgesic, antiserotonic and blood-pressure-lowering effects. Their preparation and pharmaceutical compositions containing them are disclosed.

  提供了通式 I 的ω-[4-(2-吡啶基)-哌嗪基]-烷酰苯胺衍生物。 式中 n = 1、2 或 3、 R、R、RZ、R3 和 R4 中的每一个独立地为 H、卤素、烷基、烷氧基、OH、NH2、CF3、CN、烷硫基、1-羟基烷基、烷酰基、NH2CO、NH2SO2、烷氧基羰基、烷基磺酰基、苄氧基、烷酰氨基、NH2CONH、3-苯基脲基、3-烷基脲基或烷基脲基。3-烷基脲或烷氧基乙酰氨基、 R5 = H 或烷基、 R6 = H 或烷氧基。 这些化合物及其药学上可接受的盐类具有抗过敏反应、抗支气管痉挛、抗组胺、镇静、镇痛、解热镇痛和降血压作用。公开了它们的制备方法和含有它们的药物组合物。
• 1-2-(Pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic and mast cell stabilizing activities
  作者：Alberto Catto、Gianni Motta、Alberto Tajana、Pietro Cazzulani、Dante Nardi、Amedeo Leonardi

  DOI：10.1021/jm00384a002

  日期：1987.1

  New 1-(2-pyridinyl)piperazine derivatives were synthesized and tested as inhibitors of the reaginic passive cutaneous anaphylaxis in the rat (PCA), of the histamine-induced bronchospasm in the guinea pig, and of the rat mesenteric mast cell degranulation induced by compound 48/80. On the basis of test results, a series of N-(substituted phenyl)-omega-[4-(2-pyridinyl)-1-piperazinyl]alkanamides was prepared. The nature of substituents at the anilide ring strongly influenced mast cell stabilizing activity, whereas it was less determining in the case of the other two tests. No clear correlation between the most common physicochemical parameters (pi, sigma, Vw volume) of substituents and activity could be detected. With regard to the position of substituents at the anilide ring, the rank order of potency, in the PCA and bronchoconstriction tests, was para greater than meta greater than ortho. Introduction of substituents in the 1-(2-pyridinyl)piperazinyl moiety of the N-(substituted phenyl)propanamide derivatives hardly affected activity, or the effect was deleterious. Some of the new compounds exhibited a simultaneous remarkable activity in all the three assays employed.
• NARDI, D.;CAZZULANI, P.;TAJANA, A.;CATTO, A.;GRAZIANI, G.
  作者：NARDI, D.、CAZZULANI, P.、TAJANA, A.、CATTO, A.、GRAZIANI, G.

  DOI：——

  日期：——
• CATTO A.; MOTTA G.; TAJANA A.; CAZZULANI P.; NARDI D.; LEONARDI A., J. MED. CHEM., 30,(1987) N 1, 13-19
  作者：CATTO A.、 MOTTA G.、 TAJANA A.、 CAZZULANI P.、 NARDI D.、 LEONARDI A.

  DOI：——

  日期：——
• ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION
  申请人：Abbott Laboratories

  公开号：EP1509213A2

  公开（公告）日：2005-03-02